Topic
drug development
60 stories related to this topic, newest first.
wwd.comscience3 days ago
Roche Halts Two Huntington’s Gene-Silencing Drug Programs
Roche stopped development of two Huntington’s disease treatments after new data did not support further testing. ARPA-H separately announced a $160 million program for custom gene-editing therapies for rare diseases.
wwd.comscience4 days ago
Prime Medicine Wins Arbitration Against Beam Therapeutics Over Gene-Editing Agreement
An arbitrator ruled that Prime Medicine's work on an AATD drug did not violate a 2019 agreement with Beam Therapeutics. The decision clears the way for Prime to begin a clinical trial this quarter.
science12 days ago
Roche Lung-Cancer Drug Candidate Outperforms Standard Treatments in Late-Stage Trial
A Roche experimental lung-cancer therapy showed better results than current standard treatments in a late-stage clinical trial. The company reported the outcome through a Wall Street Journal account.
LI
forbes.comscience13 days ago
Eli Lilly Leads $100 Million Round in AI Drug Developer Absci
Eli Lilly participated in a $100 million stock offering for Absci, an AI-focused drug company. The investment targets development of an injectable antibody for hair loss and endometriosis.
science13 days ago
Amylyx and Biogen to Release Biotech Trial Results This Quarter
Stat reported upcoming data from Amylyx's Phase 3 study of avexitide and detailed results from Biogen's mid-stage Alzheimer's trial. The events form part of the publication's third-quarter biotech scorecard.
theverge.comai13 days ago
Anthropic Launches Pre-Clinical Drug Programs for Neglected Diseases and New Claude Science App
The AI company launched Claude Science on June 30 and said it will start its own drug programs. Executives said the effort will give the firm direct experience applying its tools to scientific problems.
forbes.comai15 days ago
Investment firm partners with AI company to develop new biotechs
Population Health Partners entered an agreement with Edison Scientific to create new biotechnology companies. The firm previously profited from a bidding war over an obesity drug startup.
Statai18 days ago
Biotech executives discuss China competition and AI use at BIO 2026
Executives at the annual BIO conference in San Diego addressed strategies for competing with Chinese biotech firms and improving returns on artificial intelligence investments.
Statscience18 days ago
Eli Lilly grants one patient access to obesity drug candidate via FDA program
Eli Lilly and the Food and Drug Administration approved compassionate-use access to retatrutide for a single individual. The decision was discussed on a weekly biotech podcast alongside topics of drug acquisitions and hair-loss treatments.
jns.orgscience21 days ago
HHS Sends Monoclonal Antibody Doses for Ebola Clinical Trial in Africa
The Department of Health and Human Services has sent doses of the monoclonal antibody MBP-134 to support a clinical trial. The trial protocol is under review by authorities in the Democratic Republic of the Congo and Uganda.
Fortunebusiness21 days ago
Insilico Medicine signs up to $2.5 billion neuroimmune-drug deal with SK Biopharmaceuticals
Insilico Medicine partnered with SK Biopharmaceuticals in a deal exceeding $2.5 billion to develop neuroimmune drugs. Insilico will apply its Pharma.AI platform while SK Biopharmaceuticals manages later development stages. The agreement marks Insilico’s largest Asia-Pacific tie-u…
newscientist.comscience25 days ago
Pancreatic Cancer Drug Extends Survival in International Study
An international study presented May 31 reported longer survival for pancreatic cancer patients taking daraxonrasib. The FDA granted early access to the drug one month earlier for selected patients.
dutchnews.nlscience28 days ago
Eli Lilly Shares Ajax Acquisition Data Showing Myelofibrosis Drug Candidate
Eli Lilly released initial clinical results from its acquisition of Ajax Therapeutics on June 15, 2026. The data position the program as a potential competitor to existing myelofibrosis treatments.
mhealth.jmir.orgpolitics29 days ago
Drug Barzolvolimab Shows Sustained Angioedema Relief in CSU Patients Seven Months After Dosing
Phase 2 data presented at a medical meeting found that barzolvolimab produced rapid and lasting reductions in angioedema for patients with antihistamine-refractory chronic spontaneous urticaria. Improvements began within one week and continued through 52 weeks of treatment, remai…
forbes.combusiness32 days ago
Simcere Pharmaceutical Signs Research Deal with Stanford Medicine on Lung Disease Therapy
Simcere Pharmaceutical Group Limited entered a collaboration agreement with Stanford Medicine on May 29, 2026, to fund early-stage research on a potential treatment for idiopathic pulmonary fibrosis. The company will provide funding and, if the study succeeds, will license the mo…
app.buzzsumo.comscience33 days ago
Tris Pharma to Present Five Studies on Experimental Pain Drug at Addiction Research Meeting
Tris Pharma announced five presentations on cebranopadol at the College on Problems of Drug Dependence meeting. The sessions will cover preclinical and clinical data on the drug's effects in pain and opioid use disorder.
theconstructionindex.co.ukscience34 days ago
Cullinan Reports Early Phase 1 Data on CLN-978 and Velinotamig in Small Cohorts of RA and SLE Patients
The Cambridge-based company released Phase 1 results showing remissions in rheumatoid arthritis and lupus patients. Plans for Phase 2a expansion and additional trials were also outlined.
thehindubusinessline.comscience38 days ago
Pfizer Reports Phase 2b Results for Monthly GLP-1 Drug Berobenatide
Pfizer's experimental GLP-1 receptor agonist berobenatide showed strong blood-sugar control and weight-loss effects in a Phase 2b trial. The company said the drug was generally well tolerated and supported further testing of once-monthly dosing.
FI
winnipegfreepress.comscience39 days ago
Revolution Medicines pancreatic cancer drug advances toward second-line use
Daraxonrasib is positioned to become the standard second-line treatment for pancreatic cancer. Questions remain about its potential use in newly diagnosed patients.
insidermonkey.comscience40 days ago
Legend Biotech shares rise over 40 percent after early in vivo CAR-T data
Legend Biotech shares rose more than 40 percent after the company released early clinical data for its in vivo CAR-T therapy targeting Non-Hodgkin’s lymphoma. The stock moved higher while most other biotech shares declined.
benzinga.comscience41 days ago
FDA Lets Vera Analyze Atacicept Phase 3 Data a Year Early as Accelerated Approval Decision Nears
Vera Therapeutics reached an agreement with the FDA to speed up analysis of its confirmatory Phase 3 study for atacicept in IgA nephropathy. A decision on accelerated approval is expected by July 7.
benzinga.comscience42 days ago
Revolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
benzinga.comscience42 days ago
Eli Lilly Adds Amylin Receptor Agonists to Camurus Collaboration Agreement
Camurus announced on June 1, 2026 that Eli Lilly exercised its option to include amylin receptor agonists in their June 2025 collaboration and license agreement. The move triggers a $5 million payment and extends Lilly's rights to Camurus' FluidCrystal technology.
benzinga.comscience44 days ago
Ivonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
finance44 days ago
Ivonescimab Plus Chemotherapy Extends Median Survival by Four Months vs Tislelizumab in Chinese Lung Cancer Trial
Data released Sunday showed ivonescimab reduced death risk by 34 percent versus a PD-1 drug plus chemotherapy. The results are being presented at the ASCO meeting.
Statscience44 days ago
BioNTech and Pfizer Present Bispecific Antibody Data at Oncology Meeting
BioNTech and Pfizer presented data on bispecific antibodies at the American Society of Clinical Oncology annual meeting. The companies highlighted results from studies involving new immunotherapies. Coverage also noted comments from an FDA official on agency operations.
The Guardianscience44 days ago
Amivantamab Shows Tumor Responses in 43 of 102 Patients with Advanced Head and Neck Cancer
An international trial found the Johnson & Johnson drug shrank or eliminated tumors in 43 of 102 patients whose disease had resisted prior chemotherapy and immunotherapy. Results will be presented Sunday at the American Society of Clinical Oncology meeting in Chicago.
medpagetoday.comscience45 days ago
FDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Statai49 days ago
BigHat Biosciences CEO Describes Limits of AI in Antibody Drug Design
Peyton Greenside, CEO of BigHat Biosciences, said AI can generate antibody designs quickly but that downstream testing still requires substantial time and expense. The company, founded in 2019, has completed projects with several large pharmaceutical partners.
foxnews.comscience50 days ago
Cancer Immunotherapy Pipeline Expands With Multiple New Drug Classes
More than 2,500 cancer immunotherapy programs are now active. Fifteen years after the first checkpoint inhibitor approval, several additional drug types have reached FDA approval or late-stage testing.
ER
ecns.cnscience52 days ago
Podcast Discusses Biotech Summit and China Competition
The weekly biotech podcast covered conversations from a recent health care and science summit. Topics included research publication practices and the role of AI in drug development.
thehindu.comscience52 days ago
Merck drug combination reduces lung cancer progression risk in trial
A Merck antibody-drug conjugate combined with Keytruda lowered the risk of tumor progression by 65 percent in a Phase 3 lung cancer study. The results come from an abstract released ahead of the American Society of Clinical Oncology meeting.
Statscience53 days ago
Biogen and Denali Parkinson’s Drug Fails Randomized Trial
Biogen and Denali Therapeutics reported that an experimental therapy targeting the LRRK2 protein did not slow Parkinson’s disease progression in a randomized study of 648 adults. The companies announced the results on May 21, 2026.
Statscience53 days ago
Merck-Kelun Drug Reduced Lung Cancer Progression Risk by 65 Percent in Trial
Phase 3 study results showed that a targeted chemotherapy developed by Kelun-Biotech and licensed to Merck reduced tumor progression risk by 65 percent in patients with advanced non-small cell lung cancer. A preliminary survival benefit was observed but requires longer follow-up…
Statscience54 days ago
FDA Leadership Changes Prompt Concerns Among Rare Disease Drug Developers
Drug industry executives and an academic expert discussed the effects of recent FDA personnel changes on rare disease drug development at a conference in San Francisco on May 20, 2026. They expressed uncertainty about clinical trial requirements and investor reactions.
fda.govscience55 days ago
FDA Encourages Shift From Animal Testing Models
The FDA is urging pharmaceutical companies to reduce reliance on animal testing. Betts Lacroix stated that current technology does not yet support complete replacement of animal models.
thehindu.comai55 days ago
AI Technology Helps Identify Treatment for Child's Rare Disease
Joanie Kraus described how artificial intelligence contributed to finding a drug for her daughter's ultra-rare condition during a presentation at the STAT Breakthrough West event. The account highlighted an emotional response from attendees.
The Sydney Morning Heraldbusiness56 days ago
Amplia Therapeutics Starts Phase 2b Trial of Narmafotinib for Pancreatic Cancer
Amplia Therapeutics has begun a Phase 2b study testing daily dosing of narmafotinib in newly diagnosed pancreatic cancer patients. The trial combines the drug with standard chemotherapy and will initially enroll 12 patients across Australian sites.
forbes.comscience57 days ago
U.S. Biotech Firms Spent $60 Billion on Chinese Drugs in First Quarter
American drug companies purchased Chinese-developed molecules at a pace that would double last year's total. The purchases have created divisions within the industry over whether to treat Chinese firms as partners or competitors.
benzinga.comfinance57 days ago
Quince Therapeutics Acquires Orphai Therapeutics and Raises Up to $187 Million
Quince Therapeutics announced the acquisition of Orphai Therapeutics and a concurrent private placement to fund development of an inhaled rapamycin formulation for pulmonary diseases. The deal brings LAM-001 into Quince's pipeline and extends the company's cash runway through 202…
english.radio.czscience57 days ago
Researchers Develop Method to Insert Nitrogen into Carbon-Hydrogen Bonds
A study published in Science describes a chemical method that selectively adds nitrogen to specific carbon-hydrogen bonds. The technique uses common chemical feedstocks and targets late-stage construction of carbon-nitrogen bonds.
SC
Forbesfinance58 days ago
Researchers Develop Molecular Glue to Reduce Activity of Hard-to-Target Proteins
University of Toronto and University of British Columbia scientists created a molecular glue that binds to one protein and alters its shape to reduce activity of a second protein. The approach was tested on ACAA1, a protein involved in fat processing, using X-ray imaging at the C…
kr-asia.comscience59 days ago
Bristol Myers Squibb Partners With China's Hengrui Pharma on Early-Stage Drug Development and Discovery
Bristol Myers Squibb will send four of its experimental drugs to China for early-stage clinical trials under the deal announced Tuesday. The companies will also collaborate to discover new medicines, with each contributing assets to the potentially multi-billion dollar partnershi…
FI
Statscience61 days ago
Biogen Advances Tau-Targeting Alzheimer’s Drug to Phase 3 Despite Mixed Phase 2 Data
Biogen reported that its drug diranersen reduced tau levels in spinal fluid and brains of patients with early-stage Alzheimer’s in a Phase 2 trial. The reductions correlated with slower cognitive decline, though the study did not meet its primary efficacy goal of showing a dose r…
rte.iescience61 days ago
CREATE Medicines Raises $122 Million to Advance CAR-T Candidates Into Human Trials
The biotechnology company, formerly known as Myeloid Therapeutics, secured the funding from Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines, cofounded by Siddhartha Mukherjee, is developing CAR-T therapies using myeloid cells to target soli…
The Independentworld61 days ago
US Cancer Centers Report Surge in Requests for Experimental Pancreatic Cancer Drug
US cancer centers are seeing increased patient requests for daraxonrasib following positive clinical trial results that showed doubled survival rates for advanced pancreatic cancer. The FDA approved an expanded access program for the drug on 1 May, three weeks after the developer…
manilatimes.netscience62 days ago
Bristol Myers Squibb Partners With Hengrui Pharma on Early-Stage Programs
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The agreement is the latest instance of a global pharmaceutical company seeking medicines from China. Separately, Viiv lost an HIV treatment patent case while other c…
wallstreetpit.comscience62 days ago
Hims Sales Miss Estimates as Telehealth Competition Increases
Hims & Hers Health reported sales that fell short of analyst expectations amid rising competition in the telehealth sector. The company is one of several firms offering online health services including weight loss and other treatments. Separately, Bristol Myers Squibb announced a…
Benzingascience63 days ago
Bristol Myers Squibb Agrees to Up to $15.2B Deal With Hengrui Pharma for 13 Early-Stage Programs
The deal covers 13 early-stage programs in oncology, hematology and immunology. Bristol Myers Squibb will pay up to $950 million in near-term payments while gaining rights to several drug candidates outside China.
Substrate placeholder — needs reviewscience64 days ago
Drug Daraxonrasib Extends Survival in Pancreatic Cancer Trial
A small clinical trial found that daraxonrasib, which blocks a family of mutant proteins, helped patients with a deadly form of pancreatic cancer live longer. The drug shrank or halted tumor growth in many participants. Nature reported the findings from the trial published in 202…
NA
prnewswire.comscience68 days ago
Entrada Duchenne Therapy Falls Short in Early Trial
Entrada Therapeutics reported that its next-generation exon-skipping drug for Duchenne muscular dystrophy did not meet expectations in an early-stage study. The company is among several developing improved treatments aimed at increasing functional dystrophin production in patient…
stockhead.com.auai76 days ago
FDA Announces Initiative to Improve Clinical Trial Efficiency with Real-Time Data Review
The Food and Drug Administration announced efforts to enhance the efficiency of clinical trials by reviewing data in real time from studies by AstraZeneca and Amgen. The agency also sought public input on a potential pilot program incorporating artificial intelligence for tasks s…
New York Postfinance79 days ago
FDA Greenlights First U.S. Trial of Ibogaine Derivative for Treating Alcohol Use Disorder
The Food and Drug Administration has greenlit the first human clinical trial of an ibogaine derivative in the United States to test its potential as a treatment for alcohol use disorder. This follows President Trump's executive order to fast-track psychedelic research. The agency…
Substrate placeholder — needs reviewscience82 days ago
Revolution Medicines Presents Strong KRAS Drug Data and Preclinical Compound Insights
Revolution Medicines shared clinical trial success for its pancreatic cancer therapy last week and preclinical data on a new compound yesterday. The company also presented strong results for its KRAS drug at the AACR meeting on April 21, 2026. Additional biotech developments incl…
ST
Substrate placeholder — needs reviewscience82 days ago
Trial Data: Nipocalimab Reduces IgG by 64% in Myasthenia Gravis Patients Over 120 Weeks
Johnson & Johnson's Imaavy (nipocalimab) showed sustained improvements in generalized myasthenia gravis through 120 weeks, according to seekingalpha.com. The treatment cut IgG levels by 64% and boosted symptom control. Imaavy is a product developed by J&J.
Substrate placeholder — needs reviewtechnology83 days ago
Startup 10x Science Raises $4.8 Million to Analyze AI-Generated Drug Candidates
10x Science, a startup founded in December 2025, announced a $4.8 million seed funding round to develop a platform for characterizing potential drug candidates generated by AI models. The platform uses algorithms and AI to interpret mass spectrometry data for biologic drugs. Foun…
TE
Substrate placeholder — needs reviewscience83 days ago
Eli Lilly Acquires Kelonia Therapeutics for $3 Billion as Biotech Sector Sees New Developments
Eli Lilly completed a $3 billion acquisition of Kelonia Therapeutics, according to reports. A venture capital partner shared the original investment memo and slide deck for Kelonia. Other biotech news includes BioAge's inflammation trial results, a Pfizer executive departure, and…
ST
news.google.comscience87 days ago
Revolution Medicines Reports Extended Survival in Pancreatic Cancer Trial
Revolution Medicines announced results from a Phase 3 study of its experimental drug daraxonrasib for advanced pancreatic adenocarcinoma. Patients treated with the drug had a median survival of 13.2 months, compared to 6.7 months for those on standard chemotherapy. The company pl…
ST
insidermonkey.comfinance88 days ago
Whitehawk Therapeutics Shares Spike After Citizens Launches Coverage with Outperform Rating
Shares of Whitehawk Therapeutics rose sharply on Thursday following the initiation of coverage by Citizens. The firm assigned a Market Outperform rating to the stock. This development comes ahead of early-stage data readouts for the company's drug candidates licensed from WuXi Bi…
Substrate placeholder — needs reviewscience92 days ago
GSK Presents Early-Stage Data on Experimental Cancer Drug and Plans Five Phase 3 Trials
GSK presented data from an early-stage clinical trial of an experimental cancer drug over the weekend. The company stated that the results support advancing the drug to five Phase 3 trials this year. This development follows initial testing to evaluate the drug's safety and preli…
ST